Valuation: Penumbra, Inc.

Market Cap 12.57B 11.26B 10.36B 9.38B 17.54B 1,194B 17.87B 124B 49.58B 628B 47.18B 46.18B 1,980B P/E 2026 *
68.7x
P/E 2027 * 52.3x
Enterprise Value 11.99B 10.74B 9.87B 8.95B 16.72B 1,138B 17.04B 118B 47.27B 599B 44.98B 44.03B 1,888B EV / Sales 2026 *
7.45x
EV / Sales 2027 * 6.56x
Free-Float
97.11%
Yield 2026 *
-
Yield 2027 * -
1 day-0.94%
1 week-1.68%
Current month+0.19%
1 month+0.19%
3 months-0.28%
6 months-2.31%
Current year+2.59%
1 week 316.35
Extreme 316.35
325.58
1 month 316.32
Extreme 316.32
325.58
Current year 290
Extreme 290
362.41
1 year 221.26
Extreme 221.26
362.41
3 years 148
Extreme 148
362.41
5 years 114.86
Extreme 114.865
362.41
10 years 56.05
Extreme 56.05
362.41
Manager TitleAgeSince
Chief Executive Officer 64 21/06/2004
President 41 01/09/2025
Director of Finance/CFO 54 02/12/2019
Director TitleAgeSince
Chairman 64 01/01/2015
Chairman 64 01/01/2005
Director/Board Member 59 01/04/2015
Date Insider Type Main position Quantity % Market Cap. Importance
15/10/26 Tax

Chairperson

-1,367 0.0035%
15/09/26 Tax

Chairperson

-1,230 0.0031%
17/08/26 Free

Chairperson

3,060 0.0078%
Change 5-day change 1-year change 3-year change Capi.($)
-0.94%-1.68%+37.75%+66.74% 12.68B
+1.56%+2.41%-14.82%+14.19% 181B
-6.38%-4.98%-20.90%+11.15% 120B
-0.59%+1.18%+6.12%+37.97% 119B
+3.42%+1.71%-42.32%+9.52% 91.44B
+0.09%-0.05%-3.04%+78.44% 63.07B
-0.46%+0.42%+8.19%+82.97% 55.8B
-0.23%-0.52%+10.31%-21.19% 54.03B
-4.30%-1.64%-12.30%+39.06% 45.38B
+0.58%+2.00%-1.07%-6.43% 34.37B
Average -0.72%+0.34%-3.21%+31.24% 77.62B
Weighted average by Cap. -0.59%+0.73%-9.81%+25.92%

Financials

2026 *2027 *
Net sales 1.61B 1.44B 1.32B 1.2B 2.24B 153B 2.29B 15.8B 6.34B 80.32B 6.03B 5.91B 253B 1.8B 1.62B 1.49B 1.35B 2.52B 171B 2.56B 17.73B 7.12B 90.13B 6.77B 6.63B 284B
Net income 184M 165M 152M 137M 257M 17.48B 262M 1.81B 726M 9.2B 691M 676M 29B 240M 215M 198M 179M 335M 22.8B 341M 2.36B 947M 12B 901M 882M 37.83B
Net Debt -585M -524M -482M -436M -816M -55.51B -831M -5.74B -2.31B -29.2B -2.19B -2.15B -92.09B -729M -653M -600M -544M -1.02B -69.19B -1.04B -7.16B -2.87B -36.39B -2.73B -2.68B -115B
Projected Income Statement - Annual - Penumbra, Inc.
Logo Penumbra, Inc.
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada, Australia and Singapore, as well as through distributors in select international markets.
Employees
4,700
Date Price Change Volume
30/10/26 $318.95 -0.94% 497,723
29/10/26 $321.97 +1.15% 672,771
28/10/26 $318.31 -1.77% 851,287
27/10/26 $324.04 -0.36% 407,848
26/10/26 $325.22 +0.26% 434,164
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Penumbra, Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
17
Last Close Price
318.95USD
Average target price
362.54USD
Spread / Average Target
+13.67%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Penumbra, Inc.